MedTrace Logo

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

NCT00770887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-08-11

No results posted yet for this study

Summary

The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.

Conditions

Interventions

PROCEDURE

Self administration

Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Planned Parenthood Federation of America

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Sujatha Prabhakaran, MD · Planned Parenthood of Southwest and Central Florida

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770887 on ClinicalTrials.gov